Novo nordisk and Anthropic collaborate to accelerate drug discovery with claude model

On September 16, 2026, Novo Nordisk announced a partnership with Anthropic to integrate its Claude large language model into drug discovery and development processes. The Danish pharmaceutical company plans to test Anthropic's models and Claude Science in its internal workflows, focusing on scientific challenges where the combination of both technologies could yield the most significant breakthroughs. Novo Nordisk CEO Mike Doustdar highlighted that AI tools can offer new research opportunities, aiding scientists in reasoning and deepening their understanding of human biology and drug mechanisms. Anthropic CEO Dario Amodei emphasized that providing researchers with safe, powerful, and trustworthy models can shorten development cycles and improve outcomes, leading to better treatments for patients. In addition to accelerating drug discovery, Novo Nordisk, which produces the weight-loss drug Wegovy, will use Anthropic's models to enhance its AI-driven software development. The company has already implemented Claude to automate clinical trial reports, reducing the time required for patient-related documentation from months to minutes. Meanwhile, the AI industry remains divided on the pace at which companies should advance these powerful technologies.